Apr 17, 2023 7:00 am EDT Kiora Pharmaceuticals Initiates Phase 2 Trial of KIO-101 for the Treatment of Ocular Presentation of Autoimmune Diseases
Mar 30, 2023 7:00 am EDT Kiora Announces the Acceptance of Late-Breaking Abstract on Phase 1b Study of KIO-301 in Retinitis Pigmentosa at The American Society of Neuroradiology 2023 Meeting
Mar 23, 2023 7:00 am EDT Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress
Mar 10, 2023 7:00 am EST Kiora Pharmaceuticals Announces the Acceptance of Three Abstracts at the 2023 ARVO Annual Meeting
Feb 7, 2023 7:00 am EST Kiora Pharmaceuticals Receives Investigational New Drug Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases
Feb 3, 2023 7:00 am EST Kiora Pharmaceuticals Enters into Two Equity Purchase Agreements with Lincoln Park Capital
Jan 9, 2023 7:00 am EST Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website
Jan 3, 2023 7:01 am EST Kiora Pharmaceuticals Completes Enrollment of Clinical Trial Evaluating KIO-201 for Persistent Corneal Epithelial Defects; Results Expected to be Reported in 1H 2023
Nov 18, 2022 8:30 am EST Kiora Pharmaceuticals Enters Into Agreements to Raise $3.12 Million From the Exercise of Previously Issued Class A Warrants
Nov 17, 2022 6:45 am EST Kiora Pharmaceuticals Doses First Patient in ABACUS Phase 1b Study Evaluating KIO-301 for Retinitis Pigmentosa